Table 7.
Evaluation of clinical characteristics on maternal outcome.
| Variable | Number of Reported Cases (Total n = 104) | |||
|---|---|---|---|---|
| Survival or Unreported (n = 97) | Death (n = 7) | p Value | ||
| Mean age | 30 | 36 | 0.118 | |
| SARS-CoV-2 RT-PCR positive | 65 (67.0%) | 7 (100%) | 0.713 | |
| Initial symptoms | Cough | 25 (25.8%) | 7 (100%) | 0.000 |
| Fever | 54 (55.7%) | 7 (100%) | 0.021 | |
| Dyspnea | 8 (8.2%) | 7 (100%) | 0.000 | |
| Sputum | 1 (1.0%) | 0 (0%) | 0.933 | |
| Sore throat | 3 (3.1%) | 0 (0%) | 0.810 | |
| Nasal obstruction | 1 (1.0%) | 0 (0%) | 0.933 | |
| Abnormal CT findings | 45 (46.4%) | 7 (100%) | 0.055 | |
| GGO | Bilateral | 17 (17.5%) | 6 (85.7%) | 0.020 |
| Unilateral | 10 (10.3%) | 0 (0%) | ||
| Positive | 23 (23.7%) | 0 (0%) | ||
| Negative | 1 (1.0%) | 0 (0%) | ||
| Treatment | Antibiotics | 20 (20.6%) | 7 (100%) | 0.000 |
| Antivirals | 11 (11.3%) | 7 (100%) | 0.000 | |
| Steroid | 3 (3.1%) | 0 (0%) | 0.810 | |
| Anticoagulant | 2 (2.1%) | 6 (85.7%) | 0.000 | |
| Hydroxychloroquine | 5 (5.2%) | 5 (71.4%) | 0.000 | |
| Delivery method | NSVD | 21 (21.6%) | 1 (14.3%) | 0.003 |
| C/sec | 48 (49.4%) | 4 (57.1%) | ||
| Obstetrical complications | Gestational DM | 3 (3.1%) | 0 (0%) | 1.000 |
| Vaginal bleeding | 1 (1.0%) | 0 (0%) | 0.933 | |
| Preeclampsia | 6 (6.2%) | 0 (0%) | 1.000 | |
| PROM | 10 (10.3%) | 0 (0%) | 0.482 | |
| Fetal distress | 14 (14.4%) | 0 (0%) | 0.352 | |
| Abortion | 3 (3.1%) | 0 (0%) | 1.000 | |
| Prematurity | 9 (9.3%) | 0 (00%) | 0.520 | |
| Pregnancy-induced hypertension | 4 (4.1%) | 0 (0%) | 0.754 | |
| Placental abruption | 1 (1.0%) | 0 (0%) | 0.933 | |
| Fetal death | 1 (1.0%) | 4 (57.1%) | 0.000 | |
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, RT-PCR: reverse transcription polymerase chain reaction, CT: computed tomography, GGO: ground glass opacities, NSVD: normal spontaneous vaginal delivery, C/sec: cesarean section, DM: diabetes mellitus, PROM: prelabor rupture of membranes, N: number.